Chronic inflammation and risk of colorectal and other obesity-related cancers: The health, aging and body composition study

International Journal of Cancer

Volumn 138, Issue 5, 2016, Pages 1118-1128

  Izano, Monika ^a,b   Wei, Esther K ^c   Tai, Caroline ^a   Swede, Helen ^e   Gregorich, Steven ^h   Harris, Tamara B ^f   Klepin, Heidi ^d   Satterfield, Suzanne ^g   Murphy, Rachel ^f   Newman, Anne B ^j   Rubin, Susan M ^a   Braithwaite, Dejana ^a,i  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c CALIFORNIA PACIFIC MEDICAL CENTER   (United States)

^d WAKE FOREST SCHOOL OF MEDICINE   (United States)

^e UNIVERSITY OF CONNECTICUT HEALTH CENTER   (United States)

^f NATIONAL INSTITUTE ON AGING   (United States)

^g UNIVERSITY OF TENNESSEE HEALTH SCIENCE CENTER   (United States)

^h UNIVERSITY OF CALIFORNIA   (United States)

ⁱ UNIVERSITY OF CALIFORNIA   (United States)

^j UNIVERSITY OF PITTSBURGH   (United States)

more..

Author keywords

cohort study; colorectal cancer; incidence; inflammatory markers

Indexed keywords

C REACTIVE PROTEIN; INTERLEUKIN 6; NONSTEROID ANTIINFLAMMATORY AGENT; TUMOR NECROSIS FACTOR ALPHA; TUMOR NECROSIS FACTOR;

AGED; ARTICLE; BODY MASS; BREAST CANCER; CANCER RISK; CHRONIC INFLAMMATION; COLORECTAL CANCER; ENDOMETRIUM CANCER; FEMALE; FOLLOW UP; HUMAN; MALE; OBESITY; OBESITY RELATED CANCER; PANCREAS CANCER; PRIORITY JOURNAL; PROSTATE CANCER; AGING; BLOOD; BODY COMPOSITION; CHRONIC DISEASE; COLORECTAL NEOPLASMS; COMPLICATION; INFLAMMATION; PROPORTIONAL HAZARDS MODEL; PROSPECTIVE STUDY; RISK;

AGED; AGING; BODY COMPOSITION; C-REACTIVE PROTEIN; CHRONIC DISEASE; COLORECTAL NEOPLASMS; FEMALE; HUMANS; INFLAMMATION; INTERLEUKIN-6; MALE; OBESITY; PROPORTIONAL HAZARDS MODELS; PROSPECTIVE STUDIES; RISK; TUMOR NECROSIS FACTOR-ALPHA;

EID: 84955683601     PISSN: 00207136     EISSN: 10970215     Source Type: Journal    
DOI: 10.1002/ijc.29868     Document Type: Article

References (56)

1. Coussens LM, Werb Z., Inflammation and cancer. Nature 2002; 420: 860-7.
2. Lu H, Ouyang W, Huang C., Inflammation, a key event in cancer development. Mol Cancer Res 2006; 4: 221-33.
3. Shacter E, Weitzman SA., Chronic inflammation and cancer. Oncology (Williston Park) 2002; 16: 217-26, 29; discussion 30-2.
4. Baron JA, Sandler RS., Nonsteroidal anti-inflammatory drugs and cancer prevention. Annu Rev Med 2000; 51: 511-23.
5. Pepys MB, Baltz ML., Acute phase proteins with special reference to C-reactive protein and related proteins (pentaxins) and serum amyloid A protein. Adv Immunol 1983; 34: 141-212.
6. Papanicolaou DA, Wilder RL, Manolagas SC, et al., The pathophysiologic roles of interleukin-6 in human disease. Ann Intern Med 1998; 128: 127-37.
7. Kundu JK, Surh YJ., Inflammation: gearing the journey to cancer. Mutat Res 2008; 659: 15-30.
8. Erlinger TP, Platz EA, Rifai N, et al., Creactive protein and the risk of incident colorectal cancer. J Am Med Assoc 2004; 291: 585-90.
9. Il'yasova D, Colbert LH, Harris TB, et al., Circulating levels of inflammatory markers and cancer risk in the health aging and body composition cohort. Cancer Epidemiol Biomarkers Prev 2005; 14: 2413-8.
10. Zhang SM, Buring JE, Lee IM, et al., Creactive protein levels are not associated with increased risk for colorectal cancer in women. Ann Intern Med 2005; 142: 425-32.
11. Ito Y, Suzuki K, Tamakoshi K, et al., Colorectal cancer and serum C-reactive protein levels: a case-control study nested in the JACC Study. J Epidemiol Japan Epidemiol Assoc 2005; 15 (Suppl 2): S185-9.
12. Otani T, Iwasaki M, Sasazuki S, et al., Plasma C-reactive protein and risk of colorectal cancer in a nested case-control study: Japan Public Health Center-based prospective study. Cancer Epidemiol Biomarkers Prev 2006; 15: 690-5.
13. Gunter MJ, Stolzenberg-Solomon R, Cross AJ, et al., A prospective study of serum C-reactive protein and colorectal cancer risk in men. Cancer Res 2006; 66: 2483-7.
14. Siemes C, Visser LE, Coebergh JW, et al., Creactive protein levels, variation in the C-reactive protein gene, and cancer risk: the Rotterdam Study. J Clin Oncol 2006; 24: 5216-22.
15. Trichopoulos D, Psaltopoulou T, Orfanos P, et al., Plasma C-reactive protein and risk of cancer: a prospective study from Greece. Cancer Epidemiol Biomarkers Prev 2006; 15: 381-4.
16. Aleksandrova K, Jenab M, Boeing H, et al., Circulating C-reactive protein concentrations and risks of colon and rectal cancer: a nested case-control study within the European Prospective Investigation into Cancer and Nutrition. Am J Epidemiol 2010; 172: 407-18.
17. Allin KH, Bojesen SE, Nordestgaard BG., Baseline C-reactive protein is associated with incident cancer and survival in patients with cancer. J Clin Oncol 2009; 27: 2217-24.
18. Heikkila K, Harris R, Lowe G, et al., Associations of circulating C-reactive protein and interleukin-6 with cancer risk: findings from two prospective cohorts and a meta-analysis. Cancer Causes & Control 2009; 20: 15-26.
19. Chan AT, Ogino S, Giovannucci EL, et al., Inflammatory markers are associated with risk of colorectal cancer and chemopreventive response to anti-inflammatory drugs. Gastroenterology 2011; 140: 799-808, quiz e11.
20. Song M, Wu K, Ogino S, et al., A prospective study of plasma inflammatory markers and risk of colorectal cancer in men. Br J Cancer 2013; 108: 1891-8.
21. Tsilidis KK, Branchini C, Guallar E, et al., Creactive protein and colorectal cancer risk: a systematic review of prospective studies. Int J Cancer 2008; 123: 1133-40.
22. Swede H, Hajduk AM, Sharma J, et al., Baseline serum C-reactive protein and death from colorectal cancer in the NHANES III cohort. Int J Cancer 2014; 134: 1862-70.
23. Ho GY, Wang T, Gunter MJ, et al., Adipokines linking obesity with colorectal cancer risk in postmenopausal women. Cancer Res 2012; 72: 3029-37.
24. Chaturvedi AK, Moore SC, Hildesheim A., Invited commentary: circulating inflammation markers and cancer risk-implications for epidemiologic studies. Am J Epidemiol 2013; 177: 14-9.
25. Brenner DR, Scherer D, Muir K, et al., A review of the application of inflammatory biomarkers in epidemiologic cancer research. Cancer Epidemiol Biomarkers Prev, 2014; 23: 1729-51.
26. Hu FB, Stampfer MJ, Rimm E, et al., Dietary fat and coronary heart disease: a comparison of approaches for adjusting for total energy intake and modeling repeated dietary measurements. Am J Epidemiol 1999; 149: 531-40.
27. Dai Z, Xu YC, Niu L., Obesity and colorectal cancer risk: a meta-analysis of cohort studies. World J Gastroenterol 2007; 13: 4199-206.
28. Kitahara CM, Berndt SI, de Gonzalez AB, et al., Prospective investigation of body mass index, colorectal adenoma, and colorectal cancer in the prostate, lung, colorectal, and ovarian cancer screening trial. J Clin Oncol 2013; 31: 2450-9.
29. Culig Z, Puhr M., Interleukin-6: a multifunctional targetable cytokine in human prostate cancer. Mol Cellular Endocrinol 2012; 360: 52-8.
30. Pischon T, Lahmann PH, Boeing H, et al., Body size and risk of colon and rectal cancer in the European Prospective Investigation Into Cancer and Nutrition (EPIC). J Natl Cancer Inst 2006; 98: 920-31.
31. Yudkin JS, Stehouwer CD, Emeis JJ, et al., Reactive protein in healthy subjects: associations with obesity, insulin resistance, and endothelial dysfunction: a potential role for cytokines originating from adipose tissue? Arteriosclerosis Thrombosis Vascular Biol 1999; 19: 972-8.
32. Festa A, D'Agostino R, Jr,., Howard G, et al., Chronic subclinical inflammation as part of the insulin resistance syndrome: the Insulin Resistance Atherosclerosis Study (IRAS). Circulation 2000; 102: 42-7.
33. Jenab M, Riboli E, Cleveland RJ, et al., Serum C-peptide, IGFBP-1 and IGFBP-2 and risk of colon and rectal cancers in the European Prospective Investigation into Cancer and Nutrition. Int J Cancer 2007; 121: 368-76.
34. Rinaldi S, Rohrmann S, Jenab M, et al., Glycosylated hemoglobin and risk of colorectal cancer in men and women, the European prospective investigation into cancer and nutrition. Cancer Epidemiol Biomarkers Prev 2008; 17: 3108-15.
35. Giovannucci E., Metabolic syndrome, hyperinsulinemia, and colon cancer: a review. Am J Clin Nutr 2007; 86: s836-42.
36. Stocks T, Lukanova A, Johansson M, et al., Components of the metabolic syndrome and colorectal cancer risk; a prospective study. Int J Obes (Lond) 2008; 32: 304-14.
37. Wong HL, Pfeiffer RM, Fears TR, et al., Reproducibility and correlations of multiplex cytokine levels in asymptomatic persons. Cancer Epidemiol Biomarkers Prev 2008; 17: 3450-6.
38. Tse BW, Scott KF, Russell PJ., Paradoxical roles of tumour necrosis factor-alpha in prostate cancer biology. Prostate Cancer 2012; 2012: 128965
39. Fajardo LF, Kwan HH, Kowalski J, et al., Dual role of tumor necrosis factor-alpha in angiogenesis. Am J Pathol 1992; 140: 539-44.
40. Bassett JK, Severi G, Baglietto L, et al., Weight change and prostate cancer incidence and mortality. Int J Cancer 2012; 131: 1711-9.
41. Stocks T, Hergens MP, Englund A, et al., Blood pressure, body size and prostate cancer risk in the Swedish Construction Workers cohort. Int J Cancer 2010; 127: 1660-8.
42. Pischon T, Boeing H, Weikert S, et al., Body size and risk of prostate cancer in the European prospective investigation into cancer and nutrition. Cancer Epidemiol Biomarkers Prev 2008; 17: 3252-61.
43. Littman AJ, White E, Kristal AR., Anthropometrics and prostate cancer risk. Am J Epidemiol 2007; 165: 1271-9.
44. Wright ME, Chang SC, Schatzkin A, et al., Prospective study of adiposity and weight change in relation to prostate cancer incidence and mortality. Cancer 2007; 109: 675-84.
45. Discacciati A, Orsini N, Wolk A., Body mass index and incidence of localized and advanced prostate cancer-a dose-response meta-analysis of prospective studies. Ann Oncol 2012; 23: 1665-71.
46. Schuurman AG, Goldbohm RA, Dorant E, et al., Anthropometry in relation to prostate cancer risk in the Netherlands Cohort Study. Am J Epidemiol 2000; 151: 541-9.
47. Haggstrom C, Stocks T, Ulmert D, et al., Prospective study on metabolic factors and risk of prostate cancer. Cancer 2012; 118: 6199-206.
48. Burton A, Martin R, Galobardes B, et al., Young adulthood body mass index and risk of cancer in later adulthood: historical cohort study. Cancer Causes Control 2010; 21: 2069-77.
49. Giovannucci E, Liu Y, Platz EA, et al., Risk factors for prostate cancer incidence and progression in the health professionals follow-up study. Int J Cancer 2007; 121: 1571-8.
50. Engeland A, Tretli S, Bjorge T., Height, body mass index, and prostate cancer: a follow-up of 950000 Norwegian men. Br J Cancer 2003; 89: 1237-42.
51. Andersson SO, Wolk A, Bergstrom R, et al., Body size and prostate cancer: a 20-year follow-up study among 135006 Swedish construction workers. J Natl Cancer Inst 1997; 89: 385-9.
52. Lee IM, Sesso HD, Paffenbarger RS. Jr., A prospective cohort study of physical activity and body size in relation to prostate cancer risk (United States). Cancer Causes Control 2001; 12: 187-93.
53. Cerhan JR, Torner JC, Lynch CF, et al., Association of smoking, body mass, and physical activity with risk of prostate cancer in the Iowa 65+ Rural Health Study (United States). Cancer Causes Control 1997; 8: 229-38.
54. Zhang X, Zhou G, Sun B, et al., Impact of obesity upon prostate cancer-associated mortality: a meta-analysis of 17 cohort studies. Oncol Lett 2015; 9: 1307-12.
55. Aleksandrova K, Pischon T, Jenab M, et al., Combined impact of healthy lifestyle factors on colorectal cancer: a large European cohort study. BMC Med 2014; 12: 168
56. Renehan AG, Flood A, Adams KF, et al., Body mass index at different adult ages, weight change, and colorectal cancer risk in the National Institutes of Health-AARP Cohort. Am J Epidemiol 2012; 176: 1130-40.